12:00 AM
Sep 28, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGN1703: Additional Phase Ib data

Additional data from 15 patients enrolled in an open-label, single and multiple dose-escalation, German Phase Ib trial showed that a single dose of 60 mg subcutaneous...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >